Skip to main content

Table 1 Characteristics of included studies

From: Clinical efficacy and safety of polymyxins based versus non-polymyxins based therapies in the infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis

Author; YearCountryStudy yearsStudy designSettingCRs MIC
/mg/L
Type of infectionMale/ FemaleAge (years)Treatment regimenSample size (PXs vs. Non-PXs)Route of colistinAPACHE II score
(mean)
Polymyxins groupNon-polymyxins group
Trottier 2007 [27]USA2004–05RSMIXNAMixb83/3317 ~ 90COLAMK; FEP; CPF; DOX; IMP; MNO; TZP96 vs. 20IV/IH/IV+
IH/IV + IT
NR
Betrosian 2008 [20]GreeceNARCTICUNAVAP14/14adultCOLSAM15 vs. 13IV14
Lopez-Cortes 2014 [23]Spain2010PSNA≥32RT/SS/SST UT/IAI/CNS OA/BmNA>18COL; COL+TGC;
COL+CRs;
COL+SUL;
COL+AG;
COL+RIF;
COL+TGC + AG;
COL+TGC+ CRs + AG
CRs; TGC; SUL; TCY;
CRs + TGC;
CRs + AG;
TGC + RIF;
TGC + AG;
TGC + CRs + RIF
52 vs. 12IVNA
Ozvatan 2016 [24]Turkey1996–2010RSNANAVAPNA≥18COL; COL+OTHM/I; SAM; CSL; OTH29 vs. 187IVNA
Zalts 2016 [14]Israel2008–09RSICUNAVAP70/28>18COLSAM66 vs. 32IV17.5
Pan 2018 [25]China2013–17RCSNANAICI30/31>18PB+ CTRM/I + AMK; M/I + TGC; M/I + CSL;
M/I + TGC + CSL; CSL; CSL + AMK;
23 vs. 38IV + IT18
Khalili 2018 [21]Iran2015–17RCTICU≥0.08VAP35/1218 ~ 75MEM + COLMEM + SAM24 vs.23IVNA
Liang 2018 [22]Taiwan2010–15RSMIXNAPmn167/71>20TGC + COLTGC; TGC + OTH; SUL; SUL + OTH110 vs. 128IV/IV+ IH23
Sipahi 2018 [26]Turkey & France2007–16RSICUNAMeg12/8>18TGC + COLTGC + NET; TGC + AMK; TGC + MEM;
TGC
8 vs. 12IV/ IV + ITNA
Chusri 2019 [13]Thailand2012–17RSMIX≥16IAI16/12>18TGC + COLTGC14 vs. 14IV15/median
Raz-Pasteur 2019 [19]Israel2013–15RCSMIXNAPmn/SST/Bm62/21
72/40
AnyCOLSAM;
TMP-SMX
59 vs. 24
59 vs. 53
IVNA
  1. AG aminoglycosides, AMK amikacin, Bm bacteremia, CNS central nervous system, COL colistin, CPF ciprofloxacin, CRs carbapenems, CSL cefoperazone-sulbactam, CTR ceftriaxone, DOX doxycycline, FEP cefepime, FQs fluoroquinolones, IAI intra-abdominal infection, ICI intracranial infection, ICU intensive care unit, IH inhaled, IMP imipenem, IT intrathecal/intracerebral, IV intravenous, Meg meningitis, MEM meropenem, M/I meropenem/imipenem, MIC minimum inhibitory concentration, MIX intensive care unit and hospital, MNO minocycline, NA not available, NET netilmicin, OA osteoarticular, OTH other antibiotics, PB polymyxin B, PCS prospective cohort study, Pmn pneumonia, PS prospective study, PXs polymyxins, RCS retrospective cohort study, RCT random clinical trial, RIF rifampicin, RS retrospective study, RT respiratory tract, SAM ampicillin-sulbactam, SST skin and soft tissue, SUL sulbactam, TCY tetracycline, TGC tigecycline, TMP-SMX trimethoprim-sulfamethoxazole, TZP piperacillin-tazobactam, UT urinary tract, VAP ventilator-associated pneumonia, vs. versus